Lithium increases bcl-2 expression in chick cochlear nucleus and protects against deafferentation-induced cell death.
Approximately 20-30% of neurons in the avian cochlear nucleus (nucleus magnocellularis) die following deafferentation (i.e. deafness produced by cochlea removal) and the remaining neurons show a decrease in soma size. Cell death is generally accepted to be a highly regulated process involving various pro-survival and pro-death molecules. One treatment that has been shown to modify the expression of these molecules is chronic administration of lithium. The present experiments examined whether lithium treatment can protect neurons from deafferentation-induced cell death. Post-hatch chicks were treated with LiCl or saline for 17 consecutive days, beginning on the day of hatching. On the 17th day, a unilateral cochlea ablation was performed. Five days following surgery, the nucleus magnocellularis neurons were counted stereologically on opposite sides of the same brains. Lithium reduced deafferentation-induced cell death by more than 50% (9.8% cell death as compared with 22.4% in saline-treated subjects). Lithium did not affect cell number on the intact side of the brain. Lithium also did not prevent the deafferentation-induced decrease in soma size, suggesting a dissociation between the mechanisms involved in the afferent control of soma size and those involved in the afferent control of cell viability. A possible mechanism for lithium's neuroprotective influence was examined in a second set of subjects. Previous studies suggest that the pro-survival molecule, bcl-2, may play a role in regulating cell death following deafferentation. Tissues from lithium- and saline-treated subjects were examined using immunocytochemistry. Chronic administration of lithium dramatically increased the expression of bcl-2 protein in nucleus magnocellularis neurons. These data suggest that lithium may impart its neuroprotective effect by altering the expression of molecules that regulate cell death.
Bush
A L
AL
Psychology Department, Program in Neuroscience, Florida State University, Tallahassee, FL 32306-1270, USA.
Hyson
R L
RL
D000344:Afferent Pathways / Q000293:injuries* / Q000503:physiopathology / Q000601:surgery; D000818:Animals; D002452:Cell Count; D016923:Cell Death / Q000187:drug effects / Q000502:physiology; D048429:Cell Size / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002645:Chickens; D003051:Cochlea / Q000293:injuries / Q000503:physiopathology / Q000601:surgery; D003056:Cochlear Nerve / Q000293:injuries / Q000503:physiopathology / Q000601:surgery; D017626:Cochlear Nucleus / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D003714:Denervation; D004195:Disease Models, Animal; D006319:Hearing Loss, Sensorineural / Q000150:complications / Q000503:physiopathology; D008094:Lithium / Q000494:pharmacology* / Q000627:therapeutic use; D009410:Nerve Degeneration / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects* / Q000378:metabolism; D016896:Treatment Outcome; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
D018696:Neuroprotective Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D008094:Lithium